Cambridge, UK; 7th June 2021

Atlantic Healthcare plc (Atlantic Healthcare), the specialist gastrointestinal (GI) pharmaceutical company focused on acquiring, developing and commercializing therapies that address unmet patient needs and rare diseases, today announces the strengthening of its Board with appointments of Robert Dow and Julian Thurston as Non-Executive Directors.

Dr Robert Dow is a senior biopharmaceutical executive with 39 years’ experience of product acquisitions and global clinical development having held senior roles at pharmaceutical and biotechnology companies, and contract research organizations (CROs). These include Head of Global Drug Development at Roche, and most recently, Chief Medical Officer PPD, one of the world’s leading CROs.

Julian Thurston, with a 40-year career based in London, UK with multi-national law firms, is one of the top global lawyers specializing in commercial transactions in the pharmaceutical sector.  He has a particular focus on international collaborations and licensing agreements covering Europe, USA, China, Japan, and other emerging markets, and has advised and acted for numerous fast-growing healthcare companies.

Allan Cambridge, Chairman commented: “I am pleased to welcome two such industry heavyweights in Rob Dow and Julian Thurston to the Board to contribute and support the execution of Atlantic Healthcare’s strategy.”

Commenting on this announcement Robert said: “I am delighted to join Atlantic Healthcare at this very exciting time. I believe the clinical data is highly supportive of the Company’s plans for completing development and regulatory approvals across its late-stage programmes. I look forward to working with its excellent Senior Leadership team to deliver these much-needed medicines to patients and building value for the company’s investors.

Commenting Julian said: “Having advised Atlantic Healthcare over a number of years, I am excited to be invited to join the Board and support execution of the company’s international growth plans, which include establishing commercialisation arrangements and partnerships for its GI product portfolio outside of the U.S./EU.”

~ ENDS ~

About Atlantic Healthcare

Atlantic Healthcare plc ( is a GI-focused specialist pharmaceutical company focused on acquiring, developing and commercializing therapeutics that address unmet patient needs and rare diseases.

The Company owns the exclusive worldwide rights to alicaforsen, a novel antisense drug in development for ulcerative colitis and Crohn’s disease, and renzapride, which has the potential to address the unmet needs of multiple patient groups suffering gastrointestinal motility disorders, including patients with Cystic Fibrosis and Systemic Scleroderma.

Led by an experienced international Board and Leadership Team who have deep roots and a proven track record in the pharmaceutical industry, Atlantic Healthcare plans to commercialize its products itself in the U.S. and Europe and through partnerships and licensing with established pharmaceutical companies in the rest of the world.

Forward Looking Statements

While Atlantic Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Atlantic Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Atlantic Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.